exalief
bial - portela ca, s.a. - acetat de eslicarbazepină - epilepsie - antiepileptice, - exalief este indicat ca terapie adjuvantă la adulți cu convulsii cu debut parțial, cu sau fără generalizare secundară.
minoxidil lavineli 20 mg/ml
lavineli farmaceutica, lda. - minoxidilum - sol. cut. - 20mg/ml - alte preparate de uz dermatologic alte preparate dermatologice
kivizidiale 40 de micrograme/ml + 5 mg/ml
pharmathen sa - croatia - combinatii (travoprostum+timololum) - pic. oft., sol. - 40micrograme/ml+5mg/ml - antiglaucomatoase si miotice agenti betablocanti
kivizidiale 40 de micrograme/ml+5 mg/ml
pharmathen sa - croatia - combinatii (travoprostum+timololum) - pic. oft., sol. - 40micrograme/ml+5mg/ml - antiglaucomatoase si miotice agenti betablocanti
olsitri 20 mg/5 mg/12,5 mg
krka, d.d., novo mesto - slovenia - combinatii (olmesartanum+amlodipinum+hct) - compr. film. - 20mg/5mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensinaei ii, combinatii
olsitri 40 mg/10 mg/12,5 mg
krka, d.d., novo mesto - slovenia - combinatii (olmesartanum+amlodipinum+hct) - compr. film. - 40mg/10mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensinaei ii, combinatii
olsitri 40 mg/10 mg/25 mg
krka, d.d., novo mesto - slovenia - combinatii (olmesartanum+amlodipinum+hct) - compr. film. - 40mg/10mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensinaei ii, combinatii
olsitri 40 mg/5 mg/12,5 mg
krka, d.d., novo mesto - slovenia - combinatii (olmesartanum+amlodipinum+hct) - compr. film. - 40mg/5mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensinaei ii, combinatii
olsitri 40 mg/5 mg/25 mg
krka, d.d., novo mesto - slovenia - combinatii (olmesartanum+amlodipinum+hct) - compr. film. - 40mg/5mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensinaei ii, combinatii
zynlonta
swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - agenți antineoplazici - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.